EQ stock forecast
Our latest prediction for Equillium Inc's stock price was made on the Aug. 31, 2022 when the stock price was at 2.72$.
In the short term (2weeks), EQ's stock price should underperform the market by -1.60%. During that period the price should oscillate between -10.62% and +10.90%.
In the medium term (3months), EQ's stock price should underperform the market by -2.20%. During that period the price should oscillate between -22.59% and +20.56%.
Get email alertsCreate a solid portfolio with EQ
About Equillium Inc
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of None$ per share.
The book value per share is 3.42$
Three months stock forecastAug. 31, 2022
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -71M | - | -44M | - | - | - | 34M | 3.42 | - | - | - |